F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease.

The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. We have also assembled an experienced development capacity.

Our complementary approaches of robotic-based whole-cell-screens and enzyme-based high throughput screens assessing genes identified via MycoBank and using our diverse compound library of more than 360,000 compounds has delivered a portfolio of molecules into our drug development processes. Currently we have one series active against important moulds with preliminary evidence of activity in vivo and other chemical series active against a broader spectrum of fungi. Numerous essential fungal genes are also being assessed as targets for anti-fungal action. This progress has been delivered by our high-calibre staff using expertise in fungal molecular biology, biochemistry, clinical microbiology, animal pharmacology and medicinal chemistry.

In late 2004 our Target Product Profiles were shared with an international panel of anti-fungal physicians who readily agreed that such compounds are needed by the infectious disease community; additional market research has established that new anti-fungal therapies are financially highly attractive.

The F2G science team is supported by a management group which brings many years of experience from the world of finance and the Pharmaceutical Industry.